Gregory Moeck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1354348/publications.pdf

Version: 2024-02-01

55	2,026	304743	233421
papers	citations	22 h-index	45 g-index

55	55	55	1756
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
2	Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	11
3	A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program. Open Forum Infectious Diseases, 2018, 5, ofy051.	0.9	16
4	Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
5	In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. Diagnostic Microbiology and Infectious Disease, 2017, 87, 349-356.	1.8	10
6	Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci. Journal of Global Antimicrobial Resistance, 2017, 9, 85-86.	2.2	3
7	Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease, 2017, 87, 121-128.	1.8	27
8	Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections. Journal of Global Antimicrobial Resistance, 2017, 9, 8-9.	2.2	5
9	In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci. Diagnostic Microbiology and Infectious Disease, 2017, 89, 168-171.	1.8	9
10	Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	8
11	Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci. Journal of Antimicrobial Chemotherapy, 2017, 72, 622-624.	3.0	16
12	Drug Development for Drug-Resistant Pathogens. , 2017, , 45-57.		0
13	Interference of Oritavancin on Coagulation Tests as Assessed In Vitro and in a Phase 1 Study of Normal Healthy Volunteers. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
14	Antibacterial Activity of Oritavancin and Daptomycin Against Clinical Isolates of Vancomycin-Resistant Enterococcus faecium in In Vitro Pharmacokinetic/Pharmacodynamic Models. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
15	Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. Antimicrobial Agents and Chemotherapy, 2016, 60, 4342-4345.	3.2	18
16	Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents, 2016, 48, 528-534.	2.5	28
17	Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility. Antimicrobial Agents and Chemotherapy, 2016, 60, 3174-3177.	3.2	14
18	In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011â€“2014. International Journal of Antimicrobial Agents, 2015, 46, 674-681.	2.5	22

#	Article	IF	Citations
19	Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide. Antimicrobial Agents and Chemotherapy, 2015, 59, 2405-2409.	3.2	18
20	Single-Dose Oritavancin Versus 7â€“10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study. Clinical Infectious Diseases, 2015, 60, 254-262.	5.8	179
21	Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. New England Journal of Medicine, 2014, 370, 2180-2190.	27.0	244
22	In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. International Journal of Antimicrobial Agents, 2014, 44, 65-68.	2.5	12
23	Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA). International Journal of Antimicrobial Agents, 2013, 41, 397-398.	2.5	5
24	Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 205-211.	3.2	34
25	Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. Journal of Antimicrobial Chemotherapy, 2012, 67, 2919-2926.	3.0	14
26	Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus. International Journal of Antimicrobial Agents, 2012, 39, 159-162.	2.5	13
27	Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci. International Journal of Antimicrobial Agents, 2012, 40, 562-563.	2.5	8
28	Genome Annotation and Intraviral Interactome for the Streptococcus pneumoniae Virulent Phage Dp-1. Journal of Bacteriology, 2011, 193, 551-562.	2.2	50
29	Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1355-1359.	2.2	25
30	Assessment of Oritavancin Serum Protein Binding across Species. Antimicrobial Agents and Chemotherapy, 2010, 54, 3481-3483.	3.2	17
31	Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing. Antimicrobial Agents and Chemotherapy, 2010, 54, 5369-5371.	3.2	92
32	Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates. International Journal of Antimicrobial Agents, 2010, 35, 93-94.	2.5	11
33	Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005â€“2008. International Journal of Antimicrobial Agents, 2010, 36, 474-476.	2.5	9
34	Characterization of the In Vitro Activity of Novel Lipoglycopeptide Antibiotics. Current Protocols in Microbiology, 2010, 16, Unit17.1.	6.5	6
35	Impact of Human Serum Albumin on Oritavancin In Vitro Activity against Enterococci. Antimicrobial Agents and Chemotherapy, 2009, 53, 2687-2689.	3.2	17
36	Oritavancin Kills Stationary-Phase and BiofilmStaphylococcus aureusCells In Vitro. Antimicrobial Agents and Chemotherapy, 2009, 53, 918-925.	3.2	152

#	Article	IF	Citations
37	Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. Journal of Antimicrobial Chemotherapy, 2009, 64, 868-870.	3.0	34
38	Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus. Antimicrobial Agents and Chemotherapy, 2009, 53, 800-804.	3.2	29
39	Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. Journal of Antimicrobial Chemotherapy, 2009, 63, 1191-1199.	3.0	119
40	Inhibition of Transcription in Staphylococcus aureus by a Primary Sigma Factor-Binding Polypeptide from Phage G1. Journal of Bacteriology, 2009, 191, 3763-3771.	2.2	21
41	Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2009, 53, 4762-4771.	3.2	60
42	Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease, 2009, 65, 207-210.	1.8	5
43	Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital. International Journal of Antimicrobial Agents, 2009, 34, 540-543.	2.5	4
44	Timeâ€“kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes. International Journal of Antimicrobial Agents, 2009, 34, 550-554.	2.5	13
45	Bisphosphonated Benzoxazinorifamycin Prodrugs for the Prevention and Treatment of Osteomyelitis. ChemMedChem, 2008, 3, 1863-1868.	3.2	22
46	Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. Bioorganic and Medicinal Chemistry, 2008, 16, 9217-9229.	3.0	40
47	Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters. Diagnostic Microbiology and Infectious Disease, 2008, 62, 92-95.	1.8	14
48	Linking Bisphosphonates to the Free Amino Groups in Fluoroquinolones: Preparation of Osteotropic Prodrugs for the Prevention of Osteomyelitis. Journal of Medicinal Chemistry, 2008, 51, 6955-6969.	6.4	67
49	Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2008, 52, 1597-1603.	3.2	87
50	Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2008, 52, 3820-3822.	3.2	63
51	Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus. Molecular Microbiology, 2006, 62, 1132-1143.	2.5	28
52	Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus. Molecular Microbiology, 2006, 62, 1764-1764.	2.5	0
53	A new class of small molecule RNA polymerase inhibitors with activity against Rifampicin-resistant Staphylococcus aureus1. Bioorganic and Medicinal Chemistry, 2006, 14, 5812-5832.	3.0	38
54	Triaminotriazine DNA helicase inhibitors with antibacterial activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1286-1290.	2.2	47

#	Article	IF	Citations
55	Antimicrobial drug discovery through bacteriophage genomics. Nature Biotechnology, 2004, 22, 185-191.	17.5	210